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Engineered bladder tissues, created with autologous
bladder cells seeded on biodegradable scaffolds, are
being developed for use in patients who need
cystoplasty. However, in individuals with organ damage
from congenital disorders, infection, irradiation, or
cancer, abnormal cells obtained by biopsy from the
compromised tissue could potentially contaminate the
engineered tissue. Thus, an alternative cell source for
construction of the neo-organ would be useful.
Although other types of stem cells have been
investigated, autologous mesenchymal stem cells
(MSCs) are most suitable to use in bladder regeneration.
These cells are often used as a cell source for bladder
repair in three ways - secreting paracrine factors,
recruiting resident cells, and trans-differentiation,
inducing MSCs to differentiate into bladder smooth
muscle cells and urothelial cells. Adult stem cell
populations have been demonstrated in bone marrow,
fat, muscle, hair follicles, and amniotic fluid. These cells
remain an area of intense study, as their potential for
therapy may be applicable to bladder disorders.
Recently, we have found stem cells in the urine and the
cells are highly expandable, and have self-renewal
capacity and paracrine properties. As a novel cell source,
urine-derived stem cells (USCs) provide advantages for
cell therapy and tissue engineering applications in
bladder tissue repair because they originate from the
urinary tract system. Importantly, USCs can be obtained
via a noninvasive, simple, and low-cost approach and
induced with high efficiency to differentiate into
bladder cells.* Correspondence: Yzhang@wakehealth.edu
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Stem cell-based therapy for bladder repair is most relevant
to congenital bladder conditions (for example, bladder
exstrophy) or conditions such as radiation damage, infec-
tion, interstitial cystitis, neuropathic small bladder disease,
and bladder cancer. Chronic bladder diseases cause re-
duced contractility and compliance, form heavy scar tis-
sue, and significantly reduce bladder volume (end-stage
bladder disease). To treat invasive malignancies or end-
stage bladder diseases, a partial or total cystectomy is
often used, followed by the creation of a neo-bladder or a
continent urinary reservoir with an intestinal segment or
gastric flap [1] to restore bladder function and increase its
volume. However, using bowel tissue for this purpose
commonly causes complications, such as excess mucus se-
cretion, urinary tract infection, stone formation, and, most
importantly, increased risk for malignancy, particularly
adenocarcinoma, because of histological changes in the in-
testinal mucosa after long-term exposure to urine. Recent
studies showed that all children with neurogenic bladder
disease are at increased risk of bladder cancer regardless
of exposure to intestine [2]. Therefore, new clinical and
surgical techniques are needed to allow these patients to
live healthier and more normal lives.
Bladder reconstruction with tissue engineering tech-
nology is possible through the use of normal autologous
bladder cells seeded on biodegradable scaffolds [3].
However, in patients with end-stage bladder diseases or
muscle-invasive bladder cancer, healthy autologous blad-
der cells might not be available. Concomitant develop-
ment of a healthy, cancer-free stem cell source and an
optimal three-dimensional nano-fibrous polymer scaffold
are promising developments for use in patients who re-
quire cystoplasty.
Stem cells have shown potential as a therapeutic strat-
egy for various tissue repairs, including of urinary blad-
der. Multiple types of cells have been used in preclinical
animal models to repair or regenerate bladder tissue,
employing either trans-differentiation or paracrine ef-
fects to stimulate endogenous cells participating in tissue. The licensee has exclusive rights to distribute this article, in any medium, for 12
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cells such as embryonic stem cells (ESCs), induced pluri-
potent stem cells (iPSCs) [4], multi-potent mesenchymal
stem cells (MSCs), bone marrow-derived mesenchymal
stromal cells (BMSC) [5-9], adipose-derived stem cells
[10], hair follicle stem cells [11,12], umbilical MSCs [13],
urothelial stem cells [14] and, most recently, urine-
derived stem cells (USCs) [15,16].
ESCs or iPSCs are naturally programmed to divide con-
tinuously and remain undifferentiated. Although these cells
can give rise to ectodermal, mesodermal, or endodermal
cell lineages, a significant risk of teratoma exists. Any un-
differentiated ESCs or iPSCs placed in the body might con-
tinue to divide in an uncontrolled manner, forming
tumors. In addition, it is time consuming (4 months) to
derive and characterize iPSCs from an individual. Further-
more, low efficiency of cell differentiation, genetic abnor-
malities, and high cost prohibit clinical applicability. Even
so, a few studies with ESCs or iPSCs for bladder tissue en-
gineering have been reported. Frimberger and colleagues
[17] reported that human embryoid body-derived stem
cells showed improved migration in the presence of mature
human bladder smooth muscle cells (SMCs) and urothelial
cells (UCs). In addition, Moad and colleagues [4] reported
the generation of human iPSCs derived from normal, age-
ing, human urinary tract tissue. These iPSCs were more ef-
ficient than skin-derived iPSCs in undergoing bladder
differentiation as shown by expression of urothelial-
specific markers (uroplakins, claudins, and cytokeratin)
and stromal smooth muscle markers (alpha-smooth-
muscle actin, calponin, and desmin), indicating the import-
ance of organ-specific iPSCs for tissue-specific studies.
Immobilized cell lines are not suitable for bladder regener-
ation due to safety concerns. Therefore, multi-potent adult
stem cells are currently used in bladder repair and
reconstruction.
Mesenchymal stem cells for bladder repair
To be used successfully in therapies, MSCs must be di-
rected to differentiate into the desired type of tissue. Three
types of bladder cells, SMCs, UCs, and endothelial cells,
are required for bladder regeneration [5-7,18-24]. Via
trans-differentiation, MSCs can give rise to all three types
in the bladder. In addition, MSCs possess paracrine ef-
fects, with anigogenic, anti-apoptosis, anti-fibrosis, anti-
inflammatory properties [5-7]. BMSCs promote angiogen-
esis and increase cell viability of implanted UCs when
both BMSCs and UCs seeded on biomaterial were trans-
planted in vivo [25]. Hypoxic stress increases generation
of several of these cytokines and growth factors [26,27].
Thus, MSCs can recruit resident stem cells participating
in tissue repair. Furthermore, MSCs purportedly exhibit
low immunogenicity, allowing allogeneic applications
[28-30].MSCs have several advantages for tissue repair [18-24]:
(i) they do not induce teratoma or malignant tumors; (ii)
they can generate a large amount of cells within 4 weeks;
(iii) they are highly efficient in giving rise to functional
bladder cells, such as SMCs; (iv) they secrete paracrine
factors that allow stem cells to be tolerated by the host’s
immune system; and (v) their use avoids general ethical
concerns that accompany use of other types of stem cells.
Although BMSCs or adipose-derived stem cells are the
most commonly used MSCs, they have some limitations,
such as low differentiation capacity (<5%) of UCs (endo-
dermal lineage), short lifespan in vitro (<10 passages in
BMSCs), and they require invasive collection procedures
[31-34]. Thus, the ideal stem cell sources for bladder re-
pair would: (i) be able to differentiate into functional UCs,
endothelial cells, and peripheral neurocytes with high effi-
ciency (these promote bladder contractility and compli-
ance ability, and restore histological structures with innate
vasculature and innervation); (ii) allow collection via a
non-invasive, simple, safe, and low-cost method; (iii) have
universal or ‘off the shelf ’ availability; and (iv) generate
tissue-specific or organ-specific stem cells from the urin-
ary tract system. Currently, it is unknown whether such a
‘perfect’ stem cell exists. We do know, however, that cer-
tain cell types are more favorable than others.
Urine-derived stem cells as a novel cell source
Although stem cells are a very small cell population, they
play an important role in replacing aged, injured, and dis-
eased cells and promoting tissue regeneration from organs
where they originate. We recently found that a subpopula-
tion of cells isolated from urine possess biological charac-
teristics similar to MSCs; that is, clonogenicity, cell
growth patterns, expansion capacity [15,35], cell surface
marker expression profiles [15], multipotent differenti-
ation capacity [16,36-40], pro-angiogenic paracrine effects
[41,42], immunomodulatory properties [43] and easily in-
duced iPSCs [44]. Thus, we have termed these cells 'urine-
derived stem cells' or USCs (Figure 1). USCs consistently
expressed MSC/pericyte markers and some key cell sur-
face markers, but not hematopoietic stem cell markers
(except for MHC-1), endothelial cell markers (CD31), or
human leukocyte antigen (locus) DR (HLA-DR). Com-
pared to other MSCs, USCs have several advantages: (i)
they can be collected using a simple, safe, low-cost and
non-invasive procedure; (ii) they display telomerase activ-
ity so that they are able to generate more cells; and (iii)
they differentiate into SMCs, UCs and endothelial cells
with high efficiency (Table 1).
Proliferation capacity of urine-derived stem cells
USCs can be obtained from voided urine and can gener-
ate a large number of cells from a single clone [37,38].
These cells possess highly proliferative capacity because
Figure 1 Schematic illustration of the origin and biological characteristics of urine-derived stem cells (USCs). USCs, a subpopulation of
cells isolated from urine, possess biological characteristics similar to mesenchymal stem cells.
Table 1 Comparison of various stem cell types used for bladder repair












Multipotent, but mainly limited














Low (<10%) Low (10%) High (60-85%) [39-41] Low
Telomerase activity
(TA)/telomere length
Cannot be detected Cannot be
detected
Up to 75% USC clones possess
TA and relatively long
telomeres
Possess TA and long
telomeres
None
Harvesting approach Invasive Invasive Non-invasive, simple, cost-low,
safe [56]
Invasive to harvest
somatic cells for iPSCs
Invasive
Pure stem cell isolation Difficult Difficult Very easy Easy None
Number of stem cells
harvested
1 MSC/104 bone marrow stromal
cells in new borns, 1 MSC/106
[19]
100-140 USC clones/24 hour




Yes Yes Yes Unknown Moderate
Immuno-modulatory
properties
Yes Yes Yes Unknown Unknown
Rejection after
implanted in vivo
No rejection reaction as allogenous or even xenogenous cells (for example,
human BMSCs, USCs) implanted in rodent, rabbit, or canine models
Likely to be rejected No rejection as
autogenous
cells
Oncogenic potential No No No Yes None
Clinic trial utility Potential Potential Potential Safety concern Yes
ASC, adipose-derived stem cell; BMSC, bone marrow-derived mesenchymal stromal cell; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell;
MSC, mesenchymal stem cell; PD, population doubling; SMC, smooth muscle cell; UC, urothelial cell; USC, urine-derived stem cell.
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mere length compared to BMSCs. Up to 75% of USCs
collected from middle-aged individuals expressed tel-
omerase activity (USCs-TA+) and retained long telomere
length [58], but USCs-TA+ decline to 50 to 60% of the
USCs in people aged 50 years old or older. USCs-TA+
can be maintained for up to 20 passages with 67 popula-
tion doublings, indicating that a single USC can generate
up to 267 cells within 14 weeks. In contrast, USCs-TA−
grow for only 8 to 10 passages with 34 population dou-
blings. Importantly, either USCs-TA+ or USCs-TA− dis-
play normal karyotypes in culture medium even after
several passages. They did not form teratomas 3 months
after renal subcapsular cell implantation [58]. We can
now obtain 100 to 140 USC clones/24 h urine from each
individual [35]. About 1.4 × 109 cells are needed for po-
tential use in bladder reconstruction with cell-seeded
technology [3]. Thus, two urine samples containing 20
to 30 USC clones in 400 ml can provide ample cells
(1.5 × 109 USCs at passage 4) within 4 to 5 weeks to be
used in cell-based therapy for bladder repair.
Multipotent differentiation potential of urine-derived
stem cells
Our data demonstrated that USCs are capable of osteo-
genic, chondrogenic and adipogenic myogenic, neuro-
genic and endothelial differentiation [15]. After being
induced in the appropriate condition in vitro, each type
of differentiated USC expressed specific markers at the
gene, protein, and cellular levels. Following implantation
in vivo, induced USCs can form functional bone, cartil-
age, fat, muscle, endothelium, and urothelium tissue
[15]. However, signaling pathways involved in USCs dif-
ferentiation and proliferation need further investigation.
Urine-derived stem cell differentiation into bladder cells
For bladder tissue engineering, urothelial cells are needed
for creating bladder mucosa, smooth muscle cells for
building up bladder wall, and endothelial cells for forming
blood vessels. However, a challenge in urological tissue re-
generation is generating urothelial cells from MSC-
derived cells. Although BMSCs, the most commonly used
MSC source, can efficiently differentiate into SMCs, only
5% of BMSCs can give rise to the cells expressing urothe-
lial markers in vitro [40]. One of the most likely reasons
for this is that true stem cells in bone marrow stromal
cells are very rare, depending on donor age (1/104 cells in
newborns, but 1/106 in older individuals). Furthermore, it
is very difficult to isolate stem cells from the large amount
of somatic cells. Anumanthan and colleagues [45] re-
ported that use of embryonic rat bladder mesenchymal
cells co-implanted with allogeneic rat BMSCs induced
bladder tissue structure with cells expressing urothelial
and muscle markers. As well as urothelial differentiationof MSCs, Nagele and colleagues [59] reported that human
urothelial cells can be harvested from bladder washings
and primary cultures of these were successfully established
from half the bladder wash samples. The cultured cells
formed multilayered urothelial sheets for potential use in
urinary tract tissue reconstruction. Recently, Drewa and
colleagues [12] found that hair follicle stem cells from rat
whisker hair follicles differentiated into cells expressing
epithelial cell markers (cytokeratin 7, cytokeratin 8, cyto-
keratin 18) during culture in UC-conditioned medium for
2 weeks in vitro.
Using the same inductive medium as in the BMSC
study [6], we found that 60 to 70% of USCs differenti-
ated into cells expressing UC-specific genes (uroplakin-
Ia/III) and protein markers, and had urothelial barrier
function and tight junction ultrastructures. Urothelial
differentiated USCs also expressed the genes encoding
ZO-1, E-cadherin, and cingulin as well as the protein
products (associated with tight junctions) in a dose- and
time-dependent manner. The barrier function of induced
USCs reached the mature function of UCs isolated from
bladder tissue 14 days after induction, significantly
higher than for non-induced USCs, indicating that the
USCs possessed stem cell plasticity.
USCs can efficiently give rise to functional cells of the
SMC lineage. Smooth muscle differentiated USCs
expressed a-SM actin and calponin, desmin and myosin,
and smoothelin at both the gene and protein levels
[15,16]. The mRNA and protein levels of these markers
increased significantly with time in differentiation media.
Functional studies demonstrated that these SMCs have
contractile properties in vitro. Myogenic differentiated
USCs formed multiple layers of SMCs beneath UC layers
when subcutaneously implanted in a nude mouse model
[15,38]. The SMCs stained positively for a-SM actin, des-
min, and myosin. Scaffolds containing urothelial differ-
entiated USCs generated stratified layers in vivo and
stained positive for uroplakin-Ia and uroplakin-III
(urothelial markers) [14,38].
We found that USCs differentiate into cells of the
endothelial lineage when grown in endothelial differenti-
ation medium containing 2 ng/ml vascular endothelial
growth factor (VEGF) for 12 days [15]. In vitro 'vessel
forming' was displayed 18 hours after differentiated
USCs (5 × 103 cells) were seeded onto Matrigel. The dif-
ferentiated cells began to express the specific gene and
protein markers of endothelial cells (CD31, vWF, KDR,
FLT-1, FLT-1, eNOS and VE-cadherin). Induced USCs
demonstrated intense immunofluorescent staining for
these markers compared to non-differentiated USCs. Im-
portantly, USCs can be efficiently differentiated into
endothelial cells with barrier function. Neovessel forma-
tion occurred after induced USCs were subcutaneously
implanted in an athymic mouse model [40,41].
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Regulatory T cells play an important role in induction of
peripheral tolerance, inhibition of pro-inflammatory im-
mune responses, and decreased immune reactions. We
recently demonstrated that USCs can impart profound
immunomodulatory effects, inhibit proliferation of per-
ipheral blood mononuclear cells (PBMNCs; T and B
cells), and secrete IL-6 and IL-8 [43]. PBMNCs prolifer-
ated when mixed with other cells due to immune stimu-
lation. The PBMNC concentration in USC wells was
much less than that in BMSC culture wells. Bromodeox-
yuridine colorimetric enzyme-linked immunosorbent as-
says showed there was less bromodeoxyuridine label in
the mixed USC and PBMNC culture wells compared to
the BMSC culture wells. CD80 and CD86 expressed on
the surface of antigen‐presenting cells interact with cyto-
toxic T lymphocyte antigen‐4 expressed on activated T
cells and mediate critical T-cell inhibitory signals. Flow
cytometry showed that 3.35% of the BMSCs were posi-
tive for CD80 (versus 1.05% of USCs), and 1.3% of the
BMSCs were positive for CD86 (versus 0.55% of USCs).
Human cytokine release arrays showed that IL-6 and IL-
8 concentrations were elevated after stimulation by
PBMNCs in USC supernatant to a greater degree than
in BMSC supernatant. IL-6 and IL-8 might be the main
immunomodulatory cytokines to target in future studies
aimed at preventing and treating diabetic bladder tissue
lesions, other immune system disorders, or rejection of
transplanted organs.
Origin of urine-derived stem cells
USCs isolated from urine obtained from the upper urin-
ary tract are similar to voided USCs in morphology, cell
phenotype, growth pattern, and differentiation capacity
[36]. We found strong evidence that the voided USCs
originate from the kidney, because cells obtained from
women who had received transplanted kidneys from
male donors contained the Y chromosome and expressed
normal renal cell markers (PAX2 and PAX8), podocytes
and parietal cells (which populate the glomerulus in kid-
ney [60-68]), and specific gene and protein markers
(synaptopodin and podocin). USCs also expressed
CD146 at a rate similar to that expressed in parietal cells
and podocytes in glomerulus, while bladder and ureter
UCs and SMCs did not, indicating that USCs are likely
transitional cells at the parietal cell/podocyte interface
originating from renal tissue. Recently, parietal cells have
been considered as stem cells in the glomeruli, display-
ing self-renewal properties and the potential to give rise
to podocytes and proximal tubular cells [60-68]. Parietal
cells are commonly obtained from kidney tissue biopsies,
but the isolation of pure parietal cells is difficult [63-68].
In chronic bladder diseases, USCs might be a good cell
source for bladder tissue regeneration because the cellsfrom the upper urinary tract are normal. For treatment
of end-stage bladder diseases or muscle-invasive bladder
cancer, using bladder tissue created with USCs would be
superior to bladder reconstruction using intestinal
segments.
Impact of angiogenic growth factors on urine-derived
stem cell ingrowth and differentiation in vivo
USCs can secrete angiogenic growth factors and cyto-
kines, but require a favorable microenvironment to do
so. We demonstrated that use of genetically modified
stem cells via transfection of the VEGF gene significantly
promoted myogenic differentiation of USCs and induced
angiogenesis and innervation [69]. However, virally de-
livered VEGF caused several side effects in our animal
model, including hyperemia, hemorrhage, and even
death [53]. Thus, a safer approach is needed for stem
cell therapy to increase angiogenesis and promote
muscle regeneration. Adding exogenous angiogenic fac-
tors into biodegradable polymers as delivery vehicles can
be beneficial to promote regeneration and tissue healing
[57]. Alginate is one of the most commonly used natural
hydrogels as an aqueous drug carrier for encapsulation
because of its mild gelling conditions and tunable micro-
sphere characteristics. Alginate microbeads also resist
protein adsorption, making them attractive for in vivo
studies [70]. Alginate microbeads deliver molecules in a
controlled fashion, which can stably release active fibro-
blast growth factor (FGF)-1 for at least 3 weeks in vitro.
This sustained release of FGF-1 promoted neovasculari-
zation in vivo without any side effects [71-73]. More re-
cently, we found that a combination of growth factors
(VEGF, insulin-like growth factor-1, FGF-1, platelet-
derived growth factor, hepatocyte growth factor and
nerve growth factor) released locally from alginate
microbeads induced USCs to differentiate into a myo-
genic lineage, enhanced revascularization and innerv-
ation, and stimulated resident cell growth in vivo [53]. In
addition, when cultured on three-dimensional biomate-
rial, stem cells had significantly enhanced cell viability,
proliferation, and differentiation in vitro, and promoted
tissue formation in vivo, compared to cells cultured on
two-dimensional plates [74].
Biomaterials for bladder tissue regeneration
Two types of biodegradable scaffolds are commonly
used in cell-seeded tissue engineering for bladder recon-
struction: natural collagen materials (that is, bladder
submucosa [75] or small intestine submucosa [39,76]
and collagen type I matrix [77]); and synthetic polymers
such as polyglycolic acid and poly(lactic-co-glycolic acid)
[3,78], biocarbon [79], poly-L-lactic acid (PLLA) [8,9]
and bacterial cellulose polymer [38]. Most degradable
biomaterials promote cellular interaction and tissue
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physical properties. However, natural collagen scaffolds
cannot maintain a robust physical structure in an in vivo
environment when used in total or subtotal bladder re-
placement, resulting in graft collapse, contraction, for-
mation of fibrosis, and shrinkage of the new bladder,
with resultant decreased bladder capacity [22]. A bioma-
terial that retains a hollow structure, and has anti-
fibrosis properties and a three-dimensional porous
microstructure for graft cell seeding would be highly de-
sirable for creating a viable tissue-engineered bladder.
An ideal biological material for urethral tissue engin-
eering would have high porosity and appropriate pore
sizes to allow cell attachment, migration and penetration
into the matrix after seeding, and it should be able to in-
duce angiogenesis, be biodegradable, histocompatible,
and have the least xenogenous antigens retained within
the matrix for minimum inflammatory potential. The
synthetic material nanofibrous PLLA appears to meet
these criteria, as it possesses a three-dimensional, highly
porous structure (50 to 200 μM), but has adequate ten-
sile strength to maintain the shape of an engineered
organ in vivo. The highly interconnected pore structure
of the nanofibrous PLLA scaffolds is an excellent envir-
onment for cell growth and angiogenesis [80,81]. This
allows abundant cell loading onto the scaffold, and in-
duces microvessel network formation, thereby promot-
ing in vivo tissue regeneration and wound healing
[82-85]. It also allows the host’s cells to participate in tis-
sue remodeling processes by encouraging infiltration or
migration into the matrix from the wound edges. Be-
cause of these properties, PLLA has been used in a num-
ber of tissue engineering studies [9,81,83,84,86-119],
including on blood vessels [86,88]. Importantly, the
nanofibrous PLLA scaffolds degrade significantly faster
than control PLLA scaffolds because of their drastically
higher surface area and fiber size [106], making them
suitable for bladder tissue regeneration.
Debated hypotheses
Several assumptions are still controversial in bladder tis-
sue regeneration research. First, trans-differentiation and
paracrine effects are both critical in regeneration of vari-
ous tissues. Although most studies have monitored the
survival rate of implanted cells, cytokines and growth
factors secreted from stem cells might play an important
role in bladder repair [120].
Second, the need for addition of growth factors to in-
duce angiogenesis is still debated. However, accumulat-
ing evidence shows that extrogenous growth factors
improve blood support and tissue repair [121,122], espe-
cially in local tissues with poor blood supply or when
large amounts of bladder tissue are being replaced.
Growth factors may not be required where the localtissue possesses a rich blood supply or when only a small
amount of bladder tissue needs replacement [22].
Third, should undifferentiated or differentiated MSCs
be used in bladder repair [19]? Undifferentiated stem
cells can secrete more paracrine factors than differenti-
ated stem cells, but differentiated cells might possess
more potential to replace dysfunctional somatic cells.
Therefore, a 1:1 ratio of undifferentiated and differenti-
ated cells might be optimal for bladder regeneration.
Fourth, both layered co-culture and sandwich co-
culture seeding techniques are used [20]. The former al-
lows the interaction of epithelial-stromal cells, whereas
the latter provides a histologic structure more similar to
the normal structure, thereby preventing SMC loss dur-
ing surgical procedures. In addition, expression of the
protein signal sonic hedgehog in urothelial basal cells
boosts and provokes increased stromal expression of
Wnt protein signals, which in turn stimulate the prolif-
eration of both urothelial and stromal cells.
Future directions
Using stem cells more efficiently for bladder regeneration
requires improving angiogenesis, inducing innervation, and
developing more suitable biomaterials in the next few years.
High short-term cell retention and long-term engraftment
after cell delivery allow more successful bladder tissue re-
pair during regeneration. Cell retention within 24 hours of
delivery in the bladder is relatively high (regardless of the
cell type or scaffolds) when SMCs are seeded on the serosal
side. However, UCs seeded on the luminal side of the scaf-
fold are often lost during surgery procedures, washed out
via the urine, or mechanically ejected via the urethral cath-
eter. In addition, successfully retained cells start to die
within the first week, most probably due to ischemia, in-
flammation, or apoptosis due to detachment from the
extracellular matrix. Therefore, it is extremely important to
increase viability of implanted stem cells early after cell
transplantation. Several methods might help reach this goal:
(i) using biomaterials with a porous micro-structure that
might protect cell retention within the scaffold; (ii) keeping
the cell-seeding scaffold construct wet in the culture media,
and avoid drying it out during surgery; (iii) inducing angio-
genesis or capillary network formation early in implantation
with angiogenic growth factors released from microbeads
or binding scaffolds in the site or using hypoxia as a pre-
treatment for implanted cells; and (iv) promoting revascu-
larization (artery-capillary-venous system) at the mid or late
stage after the implantation with biologically safe physical
stimulation, including lower-frequency electrical stimula-
tion or low-intensity ultrasound. These methods could ex-
tend the lifespan of implanted cells in vivo to provide better
tissue repair with long-term release of paracrine factors and
trans-differentiation, anti-fibroblast formation, and anti-
inflammatory and anti-apoptotic effects of MSCs. In
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der. Stimulating peripheral nerve growth into neo bladder
tissue might be more efficacious than attempting to create
neurogenic differentiation of MSCs.Conclusion
Use of MSCs, which possess an excellent safety profile, for
bladder tissue regeneration is highly feasible. Pre-clinical
outcomes have been generally positive in restoring bladder
contractility and volume in the partial (40%) cystoplasty
model. Autologous MSCs derived from patients would be a
potential cell source for bladder repair. MSCs appear safe
to use for urological tissue repair with no evidence of in-
creased tumorigenesis after implantation. USCs possess
MSC features, including self-renewal, multi-differentiation
potential, and paracrine effects. As a novel cell source,
USCs can be obtained via a non-invasive, simple, safe and
low-cost approach, are highly expandable, give rise to blad-
der cells efficiently, and express telomerase activity but do
not induce teratomas. Studies of implanted USCs in vivo
will help to determine their impact on bladder tissue regen-
eration and monitor cell retention and engraftment over
the longer term (beyond 3 months). Besides bladder tissue
repair, USCs might also be a viable cell source for uretera
or urethral tissue engineering and reconstruction, and for
cell therapy in treatment of diabetic erectile dysfunction,
vesicoureteral or anal reflux and other diseases.Note: This article is part of a thematic series on Stem cells
in genitourinary regeneration edited by John Jackson.
Other articles in the series can be found online at http://
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